Breast Cancer Start-up Challenge
Connect with Us
  • Winning Teams
  • Startups Launched
  • Phases
    • Start-up Phase
    • Eligibility & Rules
  • Resources
    • Inventions >
      • 1 Diagnostic from biopsies with software analysis
      • 2 Immunotherapy Using Modified Self Tumor Cells
      • 3 Combination of Tissue Reconstruction and Recurrence Prevention
      • 4 Human monoclonal Antibody Based Cancer Therapies
      • 5 Immunotherapy Using Granulysin Activated Monocytes
      • 6 Anti-cancer Toxin
      • 7 Versatile Delivery Method for Cancer Therapeutics
      • 8 Genomic Based Diagnostic Assay
      • 9 Tissue-based Diagnostic Assay
      • 10 Diagnostic Kit for Therapy Benefit Prediction
    • Seed Funders
  • Media
    • News and Past Events
  • Team Blogs
  • Teams
    • Teams Accepted
    • Core Team
    • Judges
    • Challenge Supporters
  • Contact Us

Orpheden Therapeutics

7/18/2014

1 Comment

 
Daniel Levine
Dan@orpheden.com
Orpheden has made exciting progress in the previous months. We worked hard to define and source vendors for our near-term operations, established strong relationships with potential angels and strategic investors, and worked with patient advocacy groups to truly understand the need for our dendritic cell therapy.  Not to mention our new online presence at www.OrphedenTherapeutics.com and on Twitter @Orpheden

Apparently we are doing something right as we have received repeated recognition for the quality of our budding business: Our license application for Granulysin-Dendritic Cells was accepted by the NIH and posted to the federal register; We were selected as a “featured company” at Techweek Chicago’s WellTECH Summit, an event followed up with national media coverage; Orpheden’s business plan was selected as a “finalist” in the iBIO PROPEL business plan competition, giving us a chance to pitch in front of over 200 investors for the grand prize in August; We pitched during the Northwestern tech transfer office’s annual meeting to their board of directors; And we were nominated for the 13th annual Chicago Innovations Awards, a prestigious entrepreneurship award given in September;

All in all, we are excited to guide Orpheden as it continues to gain momentum towards a flourishing pharmaceutical company.
1 Comment
Eva Jones link
6/9/2017 04:39:10 am

Dear Colleague,

We would like to invite your team as a delegates/ speakers,

On behalf of Organizing Committee, we take this opportunity in extending a warm and cordial welcome to you to be part of “7th European Regenerative Medicine Conference”, held conjointly with multifarious scientific associations, eminent researchers and scholars from all around the globe during October 02-04, 2017 TRYP Barcelona Aeropuerto, Barcelona, Spain. It is an immense pleasure and privilege having you here with us to honor your hard-earned scientific discoveries, innovations and would like you to share, extend and impart your valuable thoughts to the global scientific community.

Hope your presence will help our speaker and attendee in gaining new scientific ideas and discoveries.
Kindly have a glance on our website for more info: http://tissuescience-regenerativemedicine.conferenceseries.com/


Awaiting your kind response,

With Best Wishes,
Eva Jones


Reply



Leave a Reply.

    Author

    Write something about yourself. No need to be fancy, just an overview.

    Archives

    November 2014
    August 2014
    July 2014
    April 2014
    February 2014
    January 2014

    Categories

    All
    Breast Cancer
    Breast Cancer Startup Challenge
    Duke
    Invention 3
    Invention 4
    Startup
    Tulane

    RSS Feed

The Center for Advancing Innovation, INC 2013